Human LPAR1

Lysophospholipid (LPA) receptors

Lysophosphatidic acid (LPA) receptors are activated by the endogenous phospholipid LPA. The first receptor, LPA₁, was identified as ventricular zone gene-1 (vzg-1) [1], This discovery represented the beginning of... [read more] the de-orphanisation of members of the endothelial differentiation gene (edg) family, as other LPA and sphingosine 1-phosphate (S1P) receptors were found. Five additional LPA receptors (LPA_2,3,4,5,6) have since been identified [2] and their gene nomenclature codified for human LPAR1, LPAR2, etc. (HUGO Gene Nomenclature Committee, HGNC) and Lpar1, Lpar2, etc. for mice (Mouse Genome Informatics Database, MGI) to reflect species and receptor function of their corresponding proteins. The crystal structure of LPA1 is solved and indicates that LPA accesses the extracellular binding pocket, consistent with its proposed delivery via autotaxin [3]. These studies have also implicated cross-talk with endocannabinoids via phosphorylated intermediates that can also activate these receptors. The binding affinities to LPA₁ of unlabeled, natural LPA and anandamide phosphate (AEAp) were measured using backscattering interferometry (pK_d = 9) [4,5]. Utilization of this method indicated affinities that were 77-fold lower than when measured using radioactivity-based protocols [6]. Targeted deletion of LPA receptors has clarified signalling pathways and identified physiological and pathophysiological roles. Multiple groups have independently published validation of all six LPA receptors described in these tables, and further validation was achieved using a distinct read-out via a novel TGFα "shedding* assay [7]. LPA has been proposed to be a ligand for GPR35 [8], supported by a study revealing that LPA modulates macrophage function through GPR35 [9]. However chemokine (C-X-C motif) ligand 17 (CXCL17) is reported to be a ligand for GPR35/CXCR8 [10]. Moreover, LPA has also been described as an agonist for the transient receptor potential (Trp) ion channels TRPV1 [11] and TRPA1 [12]. All of these proposed non-GPCR receptor identities require confirmation and are not currently recognized as bona fide LPA receptors.

References

1. Hecht JH, Weiner JA, Post SR, et al. Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. J Cell Biol 1996;135:1071-83.
2. Mizuno H, Kihara Y. Druggable Lipid GPCRs: Past, Present, and Prospects. Adv Exp Med Biol 2020;1274:223-258.
3. Chrencik JE, Roth CB, Terakado M, et al. Crystal Structure of Antagonist Bound Human Lysophosphatidic Acid Receptor 1. Cell 2015;161:1633-43.
4. Mizuno H, Kihara Y, Kussrow A, et al. Lysophospholipid G protein-coupled receptor binding parameters as determined by backscattering interferometry. J Lipid Res 2019;60:212-217.
5. Ray M, Nagai K, Kihara Y, et al. Unlabeled lysophosphatidic acid receptor binding in free solution as determined by a compensated interferometric reader. J Lipid Res 2020;61:1244-1251.
6. Yanagida K, Masago K, Nakanishi H, et al. Identification and characterization of a novel lysophosphatidic acid receptor, p2y5/LPA6. J Biol Chem 2009;284:17731-41.
7. Inoue A, Ishiguro J, Kitamura H, et al. TGFα shedding assay: an accurate and versatile method for detecting GPCR activation. Nat Methods 2012;9:1021-9.
8. Oka S, Ota R, Shima M, et al. GPR35 is a novel lysophosphatidic acid receptor. Biochem Biophys Res Commun 2010;395:232-7.
9. Kaya B, Doñas C, Wuggenig P, et al. Lysophosphatidic Acid-Mediated GPR35 Signaling in CX3CR1⁺ Macrophages Regulates Intestinal Homeostasis. Cell Rep 2020;32:107979.
10. Maravillas-Montero JL, Burkhardt AM, Hevezi PA, et al. Cutting edge: GPR35/CXCR8 is the receptor of the mucosal chemokine CXCL17. J Immunol 2015;194:29-33.
11. Nieto-Posadas A, Picazo-Juárez G, Llorente I, et al. Lysophosphatidic acid directly activates TRPV1 through a C-terminal binding site. Nat Chem Biol 2012;8:78-85.
12. Kittaka H, Uchida K, Fukuta N, et al. Lysophosphatidic acid-induced itch is mediated by signalling of LPA₅ receptor, phospholipase D and TRPA1/TRPV1. J Physiol (Lond.) 2017;595:2681-2698.

[close]